What’s Going on with Arbutus Biopharma Corporation?
Arbutus Biopharma Corporation (ABUS) announced in a June 26 press release a bevy of new data about its AB-729 and AB-836 programs at the European Association for the Study of the Liver (EASL) International Liver Congress 2021. ABUS shares increased 13.95% pre-market today, up to $3.84 a share.
What Does This Mean for ABUS?
Arbutus Biopharma Corporation presented five abstracts (posters plus one oral presentation) at the EASL congress. The biopharmaceutical firm is focused on developing cures for people suffering from chronic hepatitis B virus (HBV) infection, along with therapies designed to tackle coronaviruses like COVID-19.
“Given our focus and commitment to the development of a cure for people living with HBV, we are gratified that all of our abstracts were selected for presentation at the Best of ILCTM,” Arbutus CEO William Collier commented. “In the second half of 2021, we look forward to the initiation of two Phase 2a proof of concept AB-729 clinical trials and to reporting initial data from both healthy volunteers and HBV subjects in our AB-836 Phase 1a/1b clinical trial. With the extensive amount of AB-729 data presented by Arbutus to date, we are confident that it has the potential to be a cornerstone drug in future HBV combination regimens.”
ABUS has an Overall Score of 52. Find out what this means to you and get the rest of the rankings on ABUS!
Arbutus Biopharma Corp is a biopharmaceutical company. The company discovers, develops, and commercializes cures for patients suffering from Hepatitis B infection. It is focused on developing a portfolio of drug candidates with multiple mechanisms of action and also involved in licensing of Lipid nanoparticle technology.